Francesco Pignatti

4.7k total citations · 1 hit paper
102 papers, 2.8k citations indexed

About

Francesco Pignatti is a scholar working on Economics and Econometrics, Oncology and Hematology. According to data from OpenAlex, Francesco Pignatti has authored 102 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Economics and Econometrics, 33 papers in Oncology and 25 papers in Hematology. Recurrent topics in Francesco Pignatti's work include Health Systems, Economic Evaluations, Quality of Life (30 papers), Statistical Methods in Clinical Trials (19 papers) and Economic and Financial Impacts of Cancer (13 papers). Francesco Pignatti is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (30 papers), Statistical Methods in Clinical Trials (19 papers) and Economic and Financial Impacts of Cancer (13 papers). Francesco Pignatti collaborates with scholars based in Netherlands, Sweden and France. Francesco Pignatti's co-authors include Richard Sylvester, Abul B.M.F. Karim, Philippe Cornu, Patrick Therasse, C. Debruyne, M. Bolla, Charles J. Vecht, Martin J. van den Bent, D Afra and Desmond Curran and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Francesco Pignatti

97 papers receiving 2.7k citations

Hit Papers

Prognostic Factors for Su... 2002 2026 2010 2018 2002 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma
    2002 657 citations Francesco Pignatti et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Francesco Pignatti Netherlands 28 854 711 612 527 479 102 2.8k
Paul G. Kluetz United States 34 1.8k 2.1× 238 0.3× 1.3k 2.0× 671 1.3× 579 1.2× 174 4.0k
Ali McBride United States 28 1.4k 1.6× 263 0.4× 516 0.8× 343 0.7× 490 1.0× 234 2.7k
Julia A. Beaver United States 39 2.7k 3.2× 264 0.4× 1.5k 2.5× 464 0.9× 1.1k 2.3× 131 4.8k
Mark D. Rothmann United States 16 443 0.5× 373 0.5× 324 0.5× 190 0.4× 445 0.9× 46 1.9k
R. Wittes United States 25 1.5k 1.7× 339 0.5× 692 1.1× 110 0.2× 473 1.0× 51 2.7k
Shenghui Tang United States 39 2.9k 3.4× 282 0.4× 1.8k 3.0× 223 0.4× 1.2k 2.5× 116 5.3k
Robert C. Kane United States 22 1.1k 1.3× 282 0.4× 434 0.7× 87 0.2× 1.4k 2.9× 32 3.0k
F. Cavalli Switzerland 33 2.2k 2.5× 444 0.6× 660 1.1× 112 0.2× 705 1.5× 147 4.0k
Eric X. Chen Canada 42 2.5k 3.0× 224 0.3× 1.6k 2.7× 215 0.4× 1.8k 3.8× 162 5.7k
Sham Mailankody United States 30 1.6k 1.9× 270 0.4× 171 0.3× 585 1.1× 1.3k 2.7× 147 3.3k

Countries citing papers authored by Francesco Pignatti

Since Specialization
Citations

This map shows the geographic impact of Francesco Pignatti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesco Pignatti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesco Pignatti more than expected).

Fields of papers citing papers by Francesco Pignatti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesco Pignatti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesco Pignatti. The network helps show where Francesco Pignatti may publish in the future.

Co-authorship network of co-authors of Francesco Pignatti

This figure shows the co-authorship network connecting the top 25 collaborators of Francesco Pignatti. A scholar is included among the top collaborators of Francesco Pignatti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesco Pignatti. Francesco Pignatti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pignatti, Francesco, Peter G. M. Mol, Chantal Quinten, et al.. (2025). Use of patient-reported outcomes to inform symptom and functional outcomes in cancer drug regulatory decisions: challenges and future directions. The Lancet Oncology. 26(6). 664–666.
2.
Norden, Yvette van, Jurjen Versluis, Anita W. Rijneveld, et al.. (2024). Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling. Cancer Medicine. 13(9). e6756–e6756. 2 indexed citations
3.
Sanz, Héctor, Wilhelmina E. Hoogendoorn, Nicolás Ballarini, et al.. (2024). Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations. Drug Safety. 47(12). 1245–1263. 2 indexed citations
4.
Tesileanu, C. Mircea S., Francesco Pignatti, Enrico Tognana, & A. J. B. Humphreys. (2023). Queries Raised During Oncology Business Pipeline Meetings at the European Medicines Agency: A 5‐Year Retrospective Analysis. Clinical Pharmacology & Therapeutics. 114(5). 1043–1049. 1 indexed citations
5.
Postmus, Douwe, et al.. (2023). Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting. European Journal of Cancer. 197. 113496–113496. 3 indexed citations
6.
Zarkavelis, George, Ciska Verbaanderd, Nathan I. Cherny, et al.. (2022). Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines. ESMO Open. 8(1). 100604–100604. 9 indexed citations
7.
Delgado, Julio, Camille Vleminckx, Jonas Bergh, et al.. (2021). The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer. ESMO Open. 6(2). 100074–100074. 12 indexed citations
8.
9.
Mueller-Berghaus, Jan, Claire Beuneu, Benjamin Hofner, et al.. (2020). EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma. The Oncologist. 25(10). 894–902. 47 indexed citations
10.
Tzogani, Kyriaki, Helga Haugom Olsen, Mats Ökvist, et al.. (2020). The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with anFLT3Mutation. The Oncologist. 25(7). e1070–e1076. 15 indexed citations
11.
Tzogani, Kyriaki, Karri Penttilä, Johanna Lähteenvuo, et al.. (2020). EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma. The Oncologist. 26(1). 70–76. 32 indexed citations
12.
Tzogani, Kyriaki, Odoardo Maria Olimpieri, Daniela Melchiorri, et al.. (2019). European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ESMO Open. 4(5). e000570–e000570. 12 indexed citations
13.
Tervonen, Tommi, Francesco Pignatti, & Douwe Postmus. (2019). From Individual to Population Preferences: Comparison of Discrete Choice and Dirichlet Models for Treatment Benefit-Risk Tradeoffs. Medical Decision Making. 39(7). 879–885. 9 indexed citations
14.
Ali, Sahra, Dominik Karres, Justin L. Hay, et al.. (2019). The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia. The Oncologist. 24(5). e171–e179. 27 indexed citations
15.
Tzogani, Kyriaki, Paula B. van Hennik, Jan Sjöberg, et al.. (2017). EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma. The Oncologist. 23(5). 631–636. 31 indexed citations
16.
Mazzucco, Walter, Claudia Marotta, Claudio Costantino, et al.. (2017). MOTIVATIONAL ASPECTS AND LEVEL OF SATISFACTION OF ITALIAN JUNIOR DOCTORS WITH REGARD TO KNOWLEDGE AND SKILLS ACQUIRED ATTENDING SPECIFIC GENERAL PRACTICE TRAINING COURSES. A NATIONAL WEB SURVEY. SHILAP Revista de lepidopterología. 4 indexed citations
17.
18.
Zafiropoulos, Nikolaos, et al.. (2012). Evaluating benefit-risk: an Agency perspective. London School of Economics and Political Science Research Online (London School of Economics and Political Science). 6 indexed citations
19.
Pignatti, Francesco, et al.. (2002). The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcome. European Journal of Clinical Pharmacology. 58(9). 573–580. 28 indexed citations
20.
Pignatti, Francesco, et al.. (2002). Clinical trials for registration in the European Union: the EMEA 5-year experience in oncology. Critical Reviews in Oncology/Hematology. 42(2). 123–135. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul G. Kluetz Breakdown of academic impact, for papers by Ali McBride Breakdown of academic impact, for papers by Julia A. Beaver Breakdown of academic impact, for papers by Mark D. Rothmann Breakdown of academic impact, for papers by R. Wittes Breakdown of academic impact, for papers by Shenghui Tang Breakdown of academic impact, for papers by Robert C. Kane Breakdown of academic impact, for papers by F. Cavalli Breakdown of academic impact, for papers by Eric X. Chen Breakdown of academic impact, for papers by Sham Mailankody
Rankless by CCL
2026